← ANALYST RATINGS · TIPRANKS

Accendra Health (ACH): analyst forecast and price target

$0.23 −9.96% close 16.10.26 · market cap $20M · Healthcare · Medical - Distribution IWM 0.01%
Price targets and ratings of

Analyst consensus

Hold

0 Buy4 Hold1 Sell

Ratings of 5 analysts in the last 3 months

12-month forecast

$1.45+517.0% upside

Based on 5 price targets given in the last 3 months, the average target is $1.45, the highest $1.50, the lowest $1.30. The average is +517.0% from the last price of $0.23.

$0.00$2.00$4.00Jan 26AprJulOctJan 27AprJulOctHigh$1.50Average$1.45Low$1.30
Highest target $1.50 Average target $1.45 Lowest target $1.30
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Michael Cherny★★★★★★★★★★#2074 · hits 57% · avg +5.7% Leerink Partners — Hold — Reiterated 18.09.26on TipRanks Sep 21 03:15 −13.8%next day −3.4% · 5 days −21.6%
Kevin Caliendo★★★★★★★★★★#2646 · hits 56% · avg +5.6% UBS $4.50 → $1.50−66.7% Hold +538.3% Reiterated 13.08.26on TipRanks 07:55 −9.8%next day −13.4% · 5 days +21.1%
Allen Lutz★★★★★★★★★★#598 · hits 67% · avg +12.3% Bank of America Securities $2.70 → $1.30−51.9% Sell +453.2% Reiterated 11.08.26on TipRanks 09:32 −9.7%next day −4.2% · 5 days −9.9%
Eric Coldwell★★★★★★★★★★#1091 · hits 59% · avg +7.7% Robert W. Baird $6.00 → $1.50−75.0% Hold +538.3% Downgrade 11.08.26on TipRanks 05:18 −9.7%next day −4.2% · 5 days −9.9%
Daniel Grosslight★★★★★★★★★★#4007 · hits 47% · avg +3.6% Citi $4.50 → $1.50−66.7% Hold +538.3% Downgrade 11.08.26on TipRanks Aug 10 16:35 −9.7%next day −4.2% · 5 days −9.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Accendra Health

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Allen Lutz★★★★★★★★★★Bank of America Securities · #598
Hits 67%216 of 324 Average return +12.3%
1 year Allen Lutz★★★★★★★★★★Bank of America Securities · #598
Hits 67%216 of 324 Average return +12.3%
2 years Allen Lutz★★★★★★★★★★Bank of America Securities · #598
Hits 67%216 of 324 Average return +12.3%

Most profitable

3 months Allen Lutz★★★★★★★★★★Bank of America Securities · #598
Hits 67%216 of 324 Average return +12.3%
1 year Allen Lutz★★★★★★★★★★Bank of America Securities · #598
Hits 67%216 of 324 Average return +12.3%
2 years Allen Lutz★★★★★★★★★★Bank of America Securities · #598
Hits 67%216 of 324 Average return +12.3%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $1.45 at a price of $0.56 (+158.0%); now: $1.45 at $0.23 (+517.0%).

$0.50$1.00$1.50Sep 15Oct 1Oct 15Top analysts$1.43Average target$1.45Price$0.23

PriceAverage targetTop analysts’ target

Recommendation trend

025710424Oct 2522Nov21Dec111Jan 261112Feb1113Mar112Apr211May21Jun211Jul131Aug141Sep41Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy222000
Buy001110
Hold111344
Sell100111

Earnings and sales forecast

Next report: 04.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.01 (from $-0.03 to $0.03). Last quarter: $-0.19.

Sales

Next quarter’s sales estimate — $618M (from $612M to $623M). Last quarter: $613M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Accendra Health
  • CEO: Kenneth Gardner-Smith
  • Employees: 6,500
  • 4435 Waterfront Drive, Glen Allen, VA, 23060, US
  • www.accendrahealth.com

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

Data from the stock’s TipRanks forecast page, read 5 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗